Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MedImmune and WuXi AppTec form JV to develop MedImmune's MEDI5117

Executive Summary

AstraZeneca PLC’s MedImmune LLC is taking advantage of an opportunity to develop and sell one of its compounds in China by creating a 50/50 joint venture with WuXi AppTec Inc. (biopharma and device R&D outsourcing). The JV will be tasked with turning out MEDI5117, an autoimmune and inflammatory disease candidate that is currently in Phase I trials in the US and Europe.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies